Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Senning procedure in a 4-month-old child with atrioventricular discordance and ventriculoarterial concordance.

JTCVS techniques·2025

Same author

Practice Patterns in Pediatric Cardiothoracic Presurgical Conferences: A Multicenter Survey Study.

Pediatric cardiology·2025

Same author

Racial and Educational Isolation are Associated with Worse Outcomes in Congenital Heart Disease.

Pediatric cardiology·2025

Same author

Racial and Educational Isolation are Associated with Worse Outcomes in Congenital Heart Disease.

Research square·2024

Same author

Heart transplantation for pediatric patients with malignant arrhythmias: Indications and outcomes.

Heart rhythm·2024

Same author

Novel linkage of the Society of Thoracic Surgeons database and hospital electronic health records.

Cardiology in the young·2024

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

Newer inotropes in pediatric heart failure.

Timothy M Hoffman¹

¹Nationwide Children's Hospital Heart Center, Columbus, OH 43205, USA. timothy.hoffman@nationwidechildrens.org

Journal of Cardiovascular Pharmacology

|March 10, 2011

Summary

Levosimendan shows promise as a pediatric inotropic agent, offering benefits similar to milrinone with favorable myocardial oxygen effects. Further pediatric studies are needed to confirm its efficacy and safety.

Related Experiment Videos

Last Updated: Jun 3, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

Area of Science:

Pediatric Cardiology
Pharmacology
Critical Care Medicine

Background:

Inotropic support in pediatric cardiac care often relies on adult data and limited evidence.
Large-scale pediatric studies on inotropic agents are scarce.
Levosimendan, a calcium sensitizer, offers inotropic and lusitropic effects.

Purpose of the Study:

To review the current understanding and potential of levosimendan in pediatric cardiac care.
To compare levosimendan's properties with existing treatments like milrinone.
To explore emerging inotropes such as istaroxime for pediatric application.

Main Methods:

Review of existing pediatric studies on levosimendan.
Analysis of levosimendan's pharmacokinetic and pharmacodynamic properties.
Comparison with adult data and other inotropic agents.

Main Results:

Pediatric levosimendan pharmacokinetics appear similar to adults.
Efficacy may be comparable or superior to milrinone.
Favorable effects on myocardial oxygen balance and potential to reduce catecholamine use were noted.
An active metabolite (OR-1876) provides a prolonged duration of action.

Conclusions:

Levosimendan presents a promising option for pediatric inotropic support.
Further clinical trials and experience are essential to establish its role.
Istaroxime is another potential lusitropic agent for future pediatric investigation.